• Ceftolozane/Tazobactam: Evidence and Clinical Meaning

  2026-09-21

  This review examines how ceftolozane/tazobactam combines potent antipseudomonal cephalosporin activity with beta-lactamase inhibition to address selected resistant gram-negative infections. Its main practical contributions are the integration of PBP pharmacology, resistance mechanisms, pharmacokinetic/pharmacodynamic targets, clinical evidence, and renal dosing considerations.

• Tofacitinib Citrate: JAK3 Research Guide

  2026-09-21

  Tofacitinib citrate, also called CP-690550 citrate, is a potent small-molecule JAK inhibitor with reported biochemical preference for JAK3. It supports immune regulation research and inflammatory disorder research, but endothelial findings show that anti-inflammatory effects do not uniformly prevent adhesion, coagulation, or cytotoxicity phenotypes.

• Reversine: Aurora Kinase Inhibitor Workflow Guide

  2026-09-20

  Reversine (SKU A3760) provides a research tool for comparing Aurora kinase A, B, and C inhibition in mitotic checkpoint, proliferation, and apoptosis workflows. It is intended for controlled in vitro and in vivo research, not for diagnostic, therapeutic, or other clinical use.

• Moxifloxacin: From Gyrase Inhibition to Translation

  2026-09-19

  Moxifloxacin offers translational researchers a practical bridge between bacterial DNA topology, mammalian cell stress, and systemic metabolic readouts. This perspective connects its fluoroquinolone mechanism with experimental design, antibiotic toxicity research, and the distinct action of gepotidacin described in structural and mechanistic studies.

• Short-Scale BIR in Fully Grown Mouse Oocytes

  2026-09-18

  The reference study identifies a short-scale form of break-induced replication in fully grown mouse oocytes and shows that DNA double-strand breaks can be amplified through Rad51-dependent and replication-dependent processes. Its combination of EdU labeling, damage-foci analysis, and pathway inhibitors provides a useful framework for distinguishing repair-associated DNA synthesis from broader replication activity.

• Tamoxifen Reprograms TAMs to Enhance Radiotherapy

  2026-09-18

  A 2026 Cancer Letters study identifies tumor-associated macrophage reprogramming as a major mechanism by which high-dose tamoxifen improves radiation efficacy in immunocompetent mice. The work links macrophage M1 polarization, CD8 T-cell activation, and tumor-derived inflammatory cytokines to JNK/c-JUN signaling, providing a rationale for ER-independent combination strategies.

• MK-1775: Measuring Checkpoint-Driven Cell Death

  2026-09-17

  Explore how MK-1775, a selective Wee1 kinase inhibitor, changes the interpretation of cancer cell-response assays. This guide connects G2 DNA damage checkpoint abrogation with time-resolved measurements of proliferation, viability, and cell killing.

• ABT-199 (GDC-0199): Practical Assay Guide

  2026-09-17

  This guide explains how to prepare, control, and interpret ABT-199 (GDC-0199), also known as Venetoclax, in BCL-2 inhibition and apoptosis workflows. It is intended for research models, including non-Hodgkin lymphoma research and acute myelogenous leukemia (AML) research, but should not be used as a clinical dosing or diagnostic protocol.

• EMD638683: From SGK1 Target to Cell Phenotype

  2026-09-16

  Explore how EMD638683, an SGK1 inhibitor, connects SGK signaling with endothelial stiffness, NDRG1 phosphorylation, and tumor-cell responses. This guide emphasizes assay interpretation, pharmacological selectivity, and practical decisions that distinguish target engagement from downstream phenotype.

• Large-Scale Gastruloid Arrays for Phenotype Screening

  2026-09-16

  Jan and colleagues developed an indexed magnetic microraft platform that enables imaging, phenotyping, and automated sorting of individual human gastruloids at scale. The study shows that the system can resolve euploid–aneuploid differences and connect image-derived phenotypes with spatial-patterning gene expression, creating a practical framework for developmental screening.

• p21-ELP1-Bac Delivery Suppresses Glioblastoma Growth

  2026-09-15

  The reference study shows that an elastin-like polypeptide and cell-penetrating peptide can deliver a p21-derived inhibitor into three glioblastoma models and suppress proliferation primarily through cytostatic effects. Its findings support intracellular peptide delivery as a strategy for restoring cell-cycle control while highlighting lineage-dependent sensitivity and the need for in vivo validation.

• Telatinib and the Next Edge in Angiogenesis Research

  2026-09-15

  Telatinib (BAY 57-9352) offers translational researchers a mechanism-aware way to study angiogenesis, invasion, and kinase-driven resistance. This article interprets recent HER2–VEGFR2 findings in triple-negative breast cancer, positions Telatinib within a multitarget research strategy, and outlines assays that can distinguish pathway engagement from nonspecific cytotoxicity.

• Cepharanthine Inhibits Endometriosis Growth

  2026-09-14

  This 2026 study evaluates the biscoclaurine alkaloid Cepharanthine across immortalized stromal cells, patient-derived endometrial organoids, and a murine peritoneal endometriosis model. Its main contribution is a cross-model mechanism linking reduced lesion growth with G0/G1 arrest, DNA damage, impaired DNA repair, and apoptosis.

• Amyloid Beta-Peptide (1-40): State-Aware Assays

  2026-09-14

  Amyloid Beta-Peptide (1-40) (human) is more than a generic neurotoxicity reagent: its molecular state can determine the biological question an assay answers. This guide combines product chemistry with a microglial signaling study to build more discriminating Alzheimer’s disease research workflows.

• In Vitro Drug Response Evaluation in Cancer

  2026-09-13

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from drug-induced cell death. Its central contribution is a more interpretable framework for designing and reporting cancer drug-response experiments, with implications for targeted and anti-angiogenic studies.

7939 records 1/530 page Next 12345 下5页 Last page